The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...

PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (VTRS) (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the ...

Some hormonal birth control products, including the vaginal ring and skin patch, may increase the risk of a blood clot, heart attack or stroke, new research suggests. A peer-reviewed study published ...